Phio Pharmaceuticals to Present Positive Phase 1b Results for PH-762 in Cutaneous Carcinomas

Phio Pharmaceuticals is scheduled to present final Phase 1b clinical results for its investigational therapy PH-762 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting on November 7, 2026. The study, which involved injecting PH-762 directly into tumors before surgery for cutaneous carcinomas, suggests the treatment is well-tolerated and may offer a tissue-sparing option for cutaneous squamous cell carcinoma. A Phase 2b study is planned for early 2027.